Danaher Corporation has secured a definitive agreement to purchase Masimo Corporation at $180 per share, totaling approximately $9.9 billion, with the deal expected to finalize in the second half of 2026. This acquisition is designed to strengthen Danaher's footprint in the medical technology sector, as Masimo is projected to achieve high-single-digit core revenue growth. Despite reporting $6.84 billion in net sales and adjusted earnings of $2.23 per share, Danaher faces challenges with a downward trend in estimates and a year-to-date stock decline of 8.6%.
“Top 5 Companies in the Point of Care Diagnostics Market · include · Sysmex, Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, Quidel Diagnostics · true”
“Danaher · reported · net sales · $6.84 billion”
“Danaher · reported · adjusted earnings · $2.23 per share”
“Danaher · had · a gross margin · 59.1%”
“Danaher · experienced · a downward trend · in fresh estimates”
“Danaher · is part of · Zacks Medical Services industry”
“Danaher · had cash and equivalents · $4.62 billion · at the end of Q4”
“Danaher · expects · adjusted core sales · to increase in the low single digits”
“Danaher · had long-term debt · $18.4 billion · at the end of the quarter”
“Masimo Corporation · will be acquired by · Danaher Corporation · $180.00 per share”
“Danaher Corporation (NYSE:DHR) · is · one of the best strong buy healthcare stocks to invest in”
“Danaher Corporation (NYSE:DHR) · approved · a regular quarterly cash dividend of $0.40 per share · on February 24, 2026”